12/5/2019 6:31:56 AM
Eli Lilly Announces New Leadership And Strategic Direction In Oncology R&D
12/2/2019 9:02:40 AM
Eli Lilly Unveils First Shared Innovation Lab, Located In South San Francisco
11/20/2019 6:31:46 AM
Lilly Announces $400 Mln Capital Investment In Manufacturing Facilities In Indianapolis; To Add About 100 Jobs
11/17/2019 10:53:32 AM
Lilly : Interim Analysis From EMPRISE Study Shows Jardiance Decreased Risk Of Hospitalization For Heart Failure
11/12/2019 8:34:34 AM
Boehringer And Lilly Initiate Study To Assess Jardiance In People Hospitalized For Acute Heart Failure
11/12/2019 7:07:40 AM
Lilly Presents 52-Week SPIRIT-H2H Data From Taltz Versus Humira Trial In Psoriatic Arthritis At ACR
11/12/2019 6:48:30 AM
Lilly : Phase 3 Study Of Taltz In Patients With Non-Radiographic Axial Spondyloarthritis Meets Primary Endpoint
11/4/2019 9:03:20 AM
Boehringer Ingelheim, Lilly Modernise Alliance To Focus Full Expertise On Jardiance
10/28/2019 10:45:25 AM
Lilly Presents Positive Results For TALTZ In Pediatric Patients With Moderate To Severe Plaque Psoriasis
10/24/2019 10:20:25 AM
Eli Lilly And Co. Commences Cash Tender Offer For Up To $2.0 Bln
10/23/2019 6:32:30 AM
Eli Lilly And Co. (LLY) Has Raised Its FY19 EPS Estimate To 5.75 - 5.85 From 5.67 - 5.77